Genentech / Roche is seeking an Associate Medical Director or Medical Director to join a team within Product Development Oncology that is investigating the use of atezolizumab (anti-
PDL1) in combination with MEK inhibition (cobimetinib) and / or BRAF inhibition (vemurafenib) in multiple tumor types including (but not limited to) melanoma, breast cancer, and multiple myeloma.
This is an exciting opportunity to drive the scientific investigation of the combination of targeted therapies and immunotherapies, as well as combinations of targeted therapies with other targeted therapies and / or chemotherapies.
Roche’s late-stage Clinical Development organization is structured by tumor type and is responsible for developing and executing both late development (Phase II III) clinical strategies that deliver medically-
differentiated therapies that provide meaningful improvement to patients. In addition, the group also develops and executes exploratory phase Ib combination studies of established agents with novel agents.
The Associate Medical Director / Medical Director role involves clinical representation on cross-functional teams responsible for the design, implementation, medical monitoring, data interpreting, reporting and publishing of studies conducted within the program.
Key Accountabilities :
Position Requirements :
Roche is an equal opportunity employer.
Research & Development, Research & Development >
threatening diseases. Genentech has multiple therapies on the market for cancer & other serious illnesses. Please take this opportunity to learn about Genentech where we believe that our employees are our most important asset & are dedicated to remaining a great place to work.
Roche is an equal opportunity employer and strictly prohibits unlawful discrimination based upon an individual’s race, color, religion, gender, sexual orientation, gender identity / expression, national origin / ancestry, age, mental / physical disability, medical condition, marital status, veteran status, or any other characteristic protected by law.